Lenalidomid Grindeks

Lenalidomide, the active ingredient in Lenalidomid Grindeks, is an immunomodulatory imide drug presented as an oral formulation for systemic use. It is employed in the treatment of multiple myeloma and certain myelodysplastic syndromes in adult patients. The product conforms to European Union quality standards and is marketed across EU member states.

GNH USA supplies Lenalidomid Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, providing reliable sourcing and regulatory support to meet clinical demand.

Lenalidomide is indicated for several hematologic malignancies and bone‑marrow failure syndromes, where it modulates immune response and inhibits tumor growth.

Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. Multiple myeloma (maintenance): prolongs remission duration following autologous stem cell transplantation. Myelodysplastic syndromes without del(5q): may be used off‑label in selected cases to improve cytopenias. Relapsed or refractory multiple myeloma: combined with dexamethasone to achieve deeper responses.

Lenalidomide is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin eruptions or itching. - Constipation: difficulty passing stools. - Nausea: upset stomach and possible vomiting. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing lenalidomide, clinicians should observe several precautionary measures to minimize risk. - Baseline blood counts: obtain complete blood count before initiation and monitor regularly. - Thromboembolic risk: assess patient history and consider prophylactic anticoagulation if risk is high. - Pregnancy potential: enforce strict contraception for both male and female patients of reproductive potential. - Renal function: adjust monitoring in patients with impaired kidney function. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Lenalidomide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of thrombosis or bleeding. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels. - Other myelosuppressive agents (e.g., chemotherapy, azacitidine): increased risk of cytopenias. - NSAIDs: may exacerbate renal toxicity.